Centre International De Recherches Dermatologiques C.i.r.d.

L'oreal

Centre International De Recherches Dermatologiques Galderma (cird

Societe Anonyme Dite: L'oreal

Groupement D'interet Economique Dit: Centre International De Recherches

Centre International De Recherches Dermatologiques Galderma

Palvella Therapeutics, Inc.

Centre International De Recherches Dermatologiques

Groupement D'interet Economique Centre International De Recherches

Centre International De Recherches Dermatologioues (cird)

Centre International De Recherches Dermatologiques Dite Cird

Galderma Research & Development Snc

Centre Internationale De Recherches Dermatologiques (c.i.r.d.)

Groupement Economique Dite: Centre National De Recherches

Groupement Economique Dit: Centre International De Recherces

Braham Shroot

Gerard Lang

Jean R Maignan

Jacques Eustache

Jean-Michel Bernardon

Serge A Restle

Michel Colin

Christopher Hensby

Serge Forestier

Gerard Malle

Alain LaGrange

Marc Barry Brown

Charles Rodney Greenaway Evans

Philippe Nedoncelle

Uwe Reichert

Wesley Harton Kaupinen

Simon David Betson

Josiane Allec

Oliver Watts

Georges Rosenbaum

Irina Safonova

Paul Grimaldi

Martine Bouclier

Jean-Francois Grollier

Rainer Schmidt

William R Pilgrim

Gerard Ailhaud

Yves-Michel Darmon

Daniel Asselineau

Daniele Caron

Michel Darmon

Jean F Grollier

Etienne Thoreau

Philippe Diaz

Bruno Charpentier

Liliane Ayache

Veronique Taupin

Yves M Darmon

Philip Green

Claude Martin

Jean-Claude Caron

Marie-Cecile Lenoir

Alain Brzokewicz

Gerald Ailhaud

Maris-Cecile Lenoir

Jesus Benavides

Marie-Therese Cavey

Joseph Gazith

Carole Le Foyer De Costil

Xavier Vige

G&eacute;rard Ailhaud

Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Anhydrous compositions of mTOR inhibitors and methods of use

Anyhydrous compositions of mTOR inhibitors and methods of use

The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-&agr; receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.

Stimulating the differentiation of preadipocytic cells and therapies based thereon

Use of benzonaphthalene derivatives to make medicaments for treating

Pigmentation of the skin, hair and/or nails of individuals is promoted by administering thereto, advantageously topically and advantageously in combination with enzymes exhibiting tyrosinase activity, effective pigmentation-promoting amounts of at least one retinoid compound which comprises a phenolic or naphtholic functional group.

Phenolic/naphtholic retinoids for promoting skin/exoskeleton pigmentation

Novel pharmaceutically/cosmetically-active polycyclic polyenic compounds have the structural formula (I): ##STR1## and are useful for modulating cellular hormone receptors.

Polycyclic polyenic compounds and pharmaceutical/cosmetic compositions

The differentiation of preadipocytic cells into adipocytic cells, in particular for correcting insulin-resistance disease states in mammalian organisms, notably in humans, for example type II diabetes and cardiovascular disorders such as hypertension and atherosclerosis, is stimulated by treating such preadipocytic cells, or a patient in need of such treatment, with an effective amount of (a) at least one ligand displaying affinity for the nuclear receptors for retinoic acid and/or isomers thereof, preferably at least one ligand displaying a specific affinity for the RAR receptors and even more preferably the RAR-.alpha. receptor and (b) at least one fatty acid, e.g., a polyunsaturated fatty acid.

Stimulating the differentiation of preadipocytic cells and therapies

Stimulating the differentiation of predipocytic cells and therapies

A polycyclic aromatic compound having the formula ##STR1## and its salts have useful therapeutic and cosmetic action particularly in psoriasis. In the formula, X represents --CH.dbd.CH--, O or S,

Polycyclic aromatic derivatives, process for preparing the same and

The invention concerns a skin substitute composed of a dermis equivalent covered with an epidermis equivalent. The dermis equivalent is a film formed from a type I collagen gel containing fibroblasts. The epidermis equivalent incorporates a basal membrane equivalent, basal layer cells, in a palisade arrangement attached to the membrane equivalent by hemidesmosomes, cells of the suprabasal layers, granular cells, and flat, keratinized cells arranged near the free surface.

Skin substitute

Growing community of inventors

Antibes, France

Braham Shroot